ARS Pharmaceuticals (SPRY) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$116.9M

Revenue (quarter)

$33.7M

Revenue growth (year over year)

+114.15%

Gross profit (trailing twelve months)

$83.5M

Gross margin

71.37%

Net income (trailing twelve months)

−$215.4M

Net income (quarter)

−$62.3M

Net income growth (year over year)

−38.89%

Net margin

−184.24%

Return on equity

−210.35%

EPS (trailing twelve months)

−$2.18

Book value per share

$0.13

P/E (trailing twelve months)

—

Price to book

31.24

Debt to assets

94.99%

Payout ratio

—

Dividend yield

—

Company profile

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

• Is ARS Pharmaceuticals (SPRY) profitable?

  No. ARS Pharmaceuticals reported a net loss of $215.4M over the trailing twelve months.

• How much revenue does ARS Pharmaceuticals (SPRY) make?

  ARS Pharmaceuticals generated $116.9M in revenue over the trailing twelve months, up 114.15% year over year.

• How do I buy stock in ARS Pharmaceuticals (SPRY)?

  SPRY trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.